• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Hypertension Drugs Market 2014-2018 - Product Image

Global Hypertension Drugs Market 2014-2018

  • ID: 2814392
  • April 2014
  • Region: Global
  • 65 pages
  • TechNavio

FEATURED COMPANIES

  • Actelion Ltd.
  • Bayer AG
  • Daiichi SankyoCo. Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • United Therapeutics Corp.
  • MORE

About Hypertension Drugs

Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary.

The analysts forecast the Global Hypertension Drugs market will grow at a CAGR of 1.2 percent over the period 2013-2018.

Covered in this Report
The Global Hypertension Drugs market can be categorized into eight segments: Diuretics, ACE Inhibitors, ARBs, CCB, Beta Blockers, Alpha Blockers, Vasodilators, and Renin Inhibitors. To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension.

The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. READ MORE >

FEATURED COMPANIES

  • Actelion Ltd.
  • Bayer AG
  • Daiichi SankyoCo. Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • United Therapeutics Corp.
  • MORE

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Rate of Incidence and Prevalence
07.1.1 Americas
07.1.2 The APAC Region
07.1.3 Europe
08. Late Stage Pipeline Snapshot
09. Market Segmentation by Mechanism of Action
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Actelion Ltd.
19.1.1 Business Overview
19.1.2 Key Information
19.1.3 SWOT Analysis
19.2 AstraZeneca plc
19.2.1 Business Overview
19.2.2 Key Information
19.2.3 SWOT Analysis
19.3 Boehringer Ingelheim GmbH
19.3.1 Business Overview
19.3.2 Business Segmentation
19.3.3 Key Information
19.3.4 SWOT Analysis
19.4 Novartis AG
19.4.1 Business Overview
19.4.2 Business Segmentation
19.4.3 Key Information
19.4.4 SWOT Analysis
19.5 Pfizer Inc.
19.5.1 Business Overview
19.5.2 Business Segmentation
19.5.3 Key Information
19.5.4 SWOT Analysis
19.6 Sanofi SA
19.6.1 Business Overview
19.6.2 Business Segmentation
19.6.3 Key Information
19.6.4 SWOT Analysis
20. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Hypertension Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Global Hypertension Drugs Market Segmentation by Mechanism of Action
Exhibit 4: Global Hypertension Drugs Market 2013
Exhibit 5: Global Hypertension Drugs Market by Geographical Segmentation 2013
Exhibit 6: Global Hypertension Drugs Market by Vendor Segmentation 2013
Exhibit 7: Business Segmentation of Boehringer Ingelheim GmbH
Exhibit 8: Business Segmentation of Novartis AG
Exhibit 9: Business Segmentation of Pfizer Inc.
Exhibit 10: Business Segmentation of Sanofi SA

FEATURED COMPANIES

  • Actelion Ltd.
  • Bayer AG
  • Daiichi SankyoCo. Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • United Therapeutics Corp.
  • MORE

Commenting on the report, an analyst from the team said: “The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease.”

According to the report, the Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies.

Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

- Actelion Ltd.
- AstraZeneca plc
- Boehringer Ingelheim GmbH
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Bayer AG
- Daiichi SankyoCo. Ltd.
- Forest Laboratories Inc.
- Merck & Co. Inc.
- Takeda Pharmaceutical Co. Ltd.
- United Therapeutics Corp.
- Valeant Pharmaceuticals International Inc.
- XOMA LLC

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos